Whitehawk Therapeutics, Inc.
corporate_fare Company Profile
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for WHWK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-06, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for WHWK spans 8-K, S-3, SCHEDULE 13D/A, 10-Q.
Recent high-impact activity:
- Whitehawk Q2 Loss Narrows to $16.6M, Cash Runway Extended to 2H 2028
- Whitehawk Q2 Loss Narrows to $16.6M, Crushing Estimates on Lower R&D Costs
- Q2 Revenue Estimate Plunges to $350K from $50M a Year Ago
- Whitehawk Therapeutics Registers 22.3M Shares for Resale by Private Placement Investors
- Whitehawk Therapeutics Secures Option for Five New ADC Programs, Bolstering Pipeline
Financial Snapshot
Short Interest & Short Volume
7.81 days to coverFINRA reported short interest of 2,487,944 shares in WHWK as of the October 30, 2026 settlement, a 5.0% decrease from the prior period — about 7.8 days to cover at its recent average daily volume. On November 19, 2026, 71.5% of WHWK volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for WHWK, detected from its recent SEC filings · based on capital-structure filings through 2026-05-29.
Resale Registration Filed · Significant Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →